Patients with HF admitted to hospital for COVID-19 had increased risk for in-hospital mortality and needed more often ICU care and intubation and mechanical ventilation compared to patients without HF.
This position paper discusses the cause and consequences of endothelial injury and dysfunction in COVID-19.
A study of 305 hospitalized COVID-19 patients showed that approximately two-third of patients with evidence of myocardial injuries had echocardiographic abnormalities. In these patients, risk of in-hospital mortality was increased.
AHA 2020 Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.
This viewpoint article in JAMA reviews the latest findings on the risk of heart failure, particularly HFpEF, in those who developed acute COVID-19 and those who have recovered from the illness.
Changes in the structure of primary care delivery, and differences in content of telemedicine visits vs. office-based visits were observed in the USA during the COVID-19 pandemic.
ESC 2020 BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.
ESC 2020 Suspension of ACEi/ARB therapy for 30 days did not impact the number of days alive and out of hospital at 30 days compared to continued use of these medications in COVID-19 patients.
ESC 2020 Although networking opportunities are poor during this year's ESC congress, there are plusses for a digital congress. Prof. Casadei lists some of them.
ESC 2020 During the COVID-19 outbreak, some areas have seen an increase in excess mortality up to 40-50%, not due to COVID-19. Prof. Casadei strongly urgues that in the future, physicians should save lives of patients they know how to save.
Prof. De Boer discusses a recent paper in JAMA Cardiol on cardiac abnormalities detected by cardiovascular MRI in 100 patients who had proven COVID-19 around 2 months ago.
Cardiovascular MRI revealed cardiac involvement in 78% of patients and ongoing myocardial inflammation in 60% of patients in an unselected cohort of 100 patients who recently recovered from COVID-19.